Drugs / LNK01002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04896112 | Apr 2021 → Oct 2022 | acquired polycythemia vera, acute myeloid leukemia, myelofibrosis, primary myelofibrosis | Lynk Pharmaceuticals Co., Ltd | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LNK01002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04896112 ↗ |
| Action | Inhibit | “triple kinase inhibitor LNK01002” NCT04896112 ↗ |
| Route | Oral | “LNK01002 will be administrated orally.” NCT04896112 ↗ |